Spero Therapeutics GAAP EPS of -$0.76 misses by $0.62
At a glance
- $SPRO today−5.43%last $0.90
- Vs industry peers−4.39 pts6-peer median −1.04% · far behind
- Since Nov 12−9.60%from the first trade after the story
- 52-week range1.7% above low$0.88 – $3.08
- Cash runway~2.5 yrs$107.9M cash ÷ $3.6M/mo burn · 10-Q
- In the headline$0.76Amount
- Key person: Filed with SEC
- Clear: legal, regulatory, security, operational, financial integrity
Early signals (2) — filed with the SEC or first reported, not yet widely covered
- Key person · SEC 8-K, Item 5.02, Nov 10: Filed: a director or officer departed, was appointed, or had their pay changed. View filing →
- Key person · SEC 8-K, Item 5.02, Oct 27: Filed: a director or officer departed, was appointed, or had their pay changed. View filing →
Close-to-close moves; beta-adjusted against the S&P 500, σ in the stock’s own daily noise; ranges one standard deviation. Reports are outlets’ words or SEC filings. Not a forecast or advice.
What it means
- What to watch: This one turns on a concrete figure ($0.76); set it against the recent trend before reading it as a turning point.
- How the stock is trading: $SPRO -5.43% in the latest session.
- Timing: It came out after the closing bell. The session change shown was settled before the story existed, and the next session is the first that could react.
Where the stock stands
Spero Therapeutics ($SPRO) dropped 5.43% to $0.90 in the latest session. Over the past month it is down 20.1%. That leaves it 71% below its 52-week high of $3.08 and 1.7% above its low of $0.88, close to the bottom of its range. The year's high was 3.5 times its low, which makes double-digit swings fairly routine here.
What the filings say
In its latest report (10-Q, filed Nov 12, 2026), $SPRO lost $44.3M over the quarter to Sep 30, 2026. Operations used $32.1M of cash over the nine months to Sep 30, 2026 — about $3.6M a month — against $107.9M in cash on Sep 30, 2026. At that pace the cash covers about 2.5 years. Total liabilities were $109.2M against $107.9M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Nov 12, the same day as this story; it is $SPRO's own account and the first thing to read. Figures are as filed with the SEC; the $SPRO page has the full statements.
How much coverage it is getting
This is one of 2 stories on Spero Therapeutics in Wook's last 30 days of coverage, including 1 this week. That is well above its usual pace: over the month it has averaged less than one a week. Going by their wording, 0 read bullish, 1 neutral and 1 bearish. This one reads bearish too, in line with most of them. This is the only one from Seeking Alpha; the rest came from other outlets.
The bigger picture
Earnings stories turn less on the headline numbers than on how they compare with what analysts expected, and on guidance for next quarter. A beat with weak guidance can land worse than a miss with a raised outlook — markets grade on the curve. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $SPRO page, and they say what management has disclosed without a reporter in between. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. To run the numbers yourself, ask Wook AI above about $SPRO: its distance from the high, its last report, or how coverage has changed.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Seeking Alpha published this on November 12, 2026. $SPRO has moved -9.60% ($0.99 to $0.90). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
